Comparative Pharmacology
Head-to-head clinical analysis: SERAX versus VALIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERAX versus VALIUM.
SERAX vs VALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
None Documented
None Documented
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine